- BPC-157 is a 15-amino-acid fragment of a gastric protective protein; TB-500 is a 7-amino-acid synthetic fragment (Ac-LKKTETQ) of thymosin beta-4, the body's main actin-binding repair protein.
- BPC-157 is best known for faster tendon and ligament healing in rats (Staresinic 2003) and for switching on VEGFR2 blood-vessel signalling (Hsieh 2017).
- Thymosin beta-4, the parent protein of TB-500, sped up rat skin wound closure by up to 61 % at day 7 (Malinda 1999) and reached phase 2 human trials for chronic ulcers.
- They work through different pathways - blood supply and fibroblast signalling for BPC-157, actin-driven cell migration for TB-500 - which is why they are often researched together.
- Neither is an approved medicine. Both are prohibited in sport by WADA at all times, and both were backed 8-6 by an FDA advisory committee for compounding eligibility in July 2026.
The short answer
BPC-157 and TB-500 are the two most researched tissue-repair peptides, and they are often mentioned in the same breath. They are not interchangeable. BPC-157 comes from the stomach and is studied mainly for tendon, ligament, gut and blood-vessel repair. TB-500 comes from thymosin beta-4, a protein found in almost every cell, and is studied mainly for cell migration and wound closure. One helps build the supply lines to a wound, the other helps cells travel into it.
Where each peptide comes from
BPC-157: a stable gastric fragment
BPC-157 (Body Protection Compound 157) is a pentadecapeptide with the sequence GEPPPGKPADDAGLV and a molar mass of about 1419.5 g/mol. It is a partial sequence of a protective protein isolated from human gastric juice by Predrag Sikiric's group at the University of Zagreb, with the first papers appearing in the early 1990s. A proline-rich stretch makes it unusually resistant to breakdown in gastric juice, which is one reason it has been studied so widely in rodents.
TB-500: a fragment of thymosin beta-4
Thymosin beta-4 is a 43-amino-acid protein (about 4.9 kDa) first sequenced from calf thymus by Low, Hu and Goldstein in 1981. It turned out to be the main G-actin-sequestering protein in mammalian cells and is released in large amounts by platelets at injury sites. TB-500 is a much shorter synthetic peptide built on the protein's actin-binding motif. A 2012 doping-control analysis from Ghent University identified the N-terminal acetylated 17-23 fragment of thymosin beta-4, Ac-LKKTETQ (about 889 g/mol), in a TB-500 product.
How they work: two different routes to repair
BPC-157 has no single identified receptor. Cell and animal work points to two main effects. First, it up-regulates and activates VEGFR2 and the downstream Akt - eNOS pathway in endothelial cells, which drives new blood-vessel growth (Hsieh, J Mol Med 2017). Second, it activates FAK - paxillin signalling in tendon fibroblasts, helping them spread and migrate into a defect (Chang, J Appl Physiol 2011). Put simply, it improves blood supply and organises the repair cells.
Thymosin beta-4 works on the cell skeleton. By binding G-actin, the building block of actin filaments, it controls how quickly cells can remodel their shape and crawl. The LKKTETQ region is the part responsible for actin binding and much of the migration and wound-healing activity. Other regions have their own effects: the N-terminal tetrapeptide Ac-SDKP is studied separately as an anti-fibrotic and anti-inflammatory fragment, which TB-500 does not contain.
What research reports for BPC-157
- Tendon: in rats with a transected Achilles tendon, BPC-157 improved load-to-failure, collagen formation and walking function at every time point up to day 14 (Staresinic, J Orthop Res 2003).
- Ligament: in a rat medial collateral ligament injury, it improved functional, biomechanical and histological healing over 90 days (Cerovecki, J Orthop Res 2010).
- Blood vessels: it increased vessel density in chick embryo and endothelial tube assays and sped up blood-flow recovery in ischemic rat hind limbs (Hsieh 2017).
- Gut: rodent studies over three decades consistently report protection and repair of the stomach and intestinal lining.
- Overall evidence: a 2025 systematic review in HSS Journal screened 544 records and included 36 studies, 35 preclinical and one clinical, and found improved muscle, tendon, ligament and bone healing in animal models with no adverse effects in preclinical safety studies.
Human data remain thin. A 2021 retrospective chart review of 16 patients with knee pain reported relief in 14, and a 2025 two-person safety pilot reported no changes in heart, liver, kidney, thyroid or glucose markers. Neither is a controlled trial, and the 2025 review found no clinical safety data.
What research reports for TB-500 and thymosin beta-4
- Skin wounds: in a rat full-thickness wound model, thymosin beta-4 increased re-epithelialisation by 42 % at day 4 and up to 61 % at day 7 versus saline, with more collagen and new vessels (Malinda, J Invest Dermatol 1999).
- Cell migration: in the same paper it stimulated keratinocyte migration 2-3-fold in vitro.
- Heart: in a 2004 Nature study, it activated integrin-linked kinase, promoted cardiac cell migration and survival and improved heart function after coronary ligation in mice.
- Hard-to-heal wounds: it accelerated healing in normal, diabetic, steroid-treated and aged rodents, and in two phase 2 trials of stasis and pressure ulcers it sped healing by almost a month in patients who healed (Treadwell, Ann N Y Acad Sci 2012).
Almost all of this evidence was generated with full-length thymosin beta-4, not with the 7-residue TB-500 fragment. That distinction matters and is covered below.
TB-500 vs thymosin beta-4: not the same molecule
The names are often used as synonyms, but they describe different molecules. Thymosin beta-4 is the natural 43-residue protein; TB-500 is a short synthetic peptide that keeps the actin-binding motif and drops the rest, including the Ac-SDKP region. The human phase 2 trials (RegeneRx formulations for wounds and, later, eye drops for dry eye) used full-length thymosin beta-4, not TB-500. When a source quotes a thymosin beta-4 result for TB-500, it is extrapolating from the parent protein. The fragment carries the domain thought to drive cell migration, but direct published data on Ac-LKKTETQ itself are limited.
Why they are researched together
Repair happens in steps: blood supply has to return, cells have to migrate in, and new matrix has to be laid down and organised. BPC-157 is linked to the vascular and fibroblast-signalling steps; thymosin beta-4 to cell migration through actin. Because the mechanisms do not overlap, researchers study them side by side to see whether covering more steps changes the outcome. This is the rationale behind our TB-500 + BPC-157 blend (10 mg + 10 mg in one vial) and the larger GLOW and KLOW blends, which add GHK-Cu and, in KLOW, KPV.
The combination itself has almost no formal data. In the 2021 knee-pain chart review, 4 patients received both peptides and 3 of the 4 reported relief. There are no controlled combination studies, so the case for pairing rests on the separate, complementary findings for each peptide.
Side-by-side comparison
| BPC-157 | TB-500 | |
|---|---|---|
| Origin | Gastric juice protein fragment | Fragment of thymosin beta-4 |
| Length | 15 amino acids | 7 amino acids (Ac-LKKTETQ) |
| Molar mass | ~1419.5 g/mol | ~889 g/mol |
| Main target | VEGFR2 - Akt - eNOS, FAK - paxillin | G-actin binding |
| Core effect | Blood-vessel growth, fibroblast signalling | Cell migration |
| Best-known model | Rat Achilles tendon, ligament, gut | Rat skin wounds, mouse heart |
| Human data | Case series and a 2-person pilot | Phase 2 trials (full-length Tβ4 only) |
| WADA | S0, banned at all times | S2, banned at all times |
| FDA (2026) | Off Category 2; PCAC vote 8-6 | Off Category 2; PCAC vote 8-6 |
Regulatory and anti-doping status
- Neither BPC-157 nor TB-500 is an approved medicine in the EU or the US, and neither has an EMA marketing authorisation.
- WADA: BPC-157 was named in section S0 (non-approved substances) in 2022, the first substance ever listed there by name. Thymosin beta-4 and its derivatives, such as TB-500, are listed under S2 growth factors. Both are prohibited in and out of competition.
- FDA: in April 2026 both peptides were removed from the Category 2 list of bulk substances that may present safety risks after their nominations were withdrawn. On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, 1 abstention to recommend each for the 503A bulks list. FDA must still run notice-and-comment rulemaking, and an advisory vote is not a drug approval.
Quality points for research material
Because TB-500 and thymosin beta-4 are easily confused, identity testing matters more than usual. LC-MS confirms which molecule is actually in the vial by its mass, while HPLC measures purity. Our BPC-157 and TB-500 + BPC-157 products are ≥99 % by HPLC with identity confirmed by LC-MS and supplied lyophilized, with an internal batch test protocol (COA) for each lot.
Research information only, not medical advice. Cryopept Labs products are for laboratory research use only.
